Company: BLRX
Filing Date: 2025-03-31
Form Type: 20-F
Source: 0001178913-25-001123
Chunk: 156

Company: BioLineRx Ltd.
Filing Date: 2025-03-31
Form: 20-F
Item: Item 3
Chunk 156
---
 of RSUs or PSUs is deferred until the transfer of the securities (or ordinary shares issued upon
the exercise of options or the vesting of RSUs or PSUs) by the trustee to the employee or upon the sale of the securities or ordinary
shares, as the case may be, and gains may qualify to be taxed as capital gains at a rate equal to 25%, subject to compliance with specified
conditions.

Options and RSUs granted under the Plan generally vest over four
years. Options generally expire 10 years from the grant date. If we terminate an employee’s employment or service for cause, all
of the grantee’s vested and unvested equity awards expire immediately from the time of delivery of the notice of discharge, unless
determined otherwise by the compensation committee or the board of directors. Upon termination of employment or service for any other
reason other than for cause, vested options may be exercised within three months of the termination date or if termination of employment
or service is due to death or disability of the employee, but in no event after the expiration date of the awards, within 12 months following
such death or disability, in each case unless otherwise determined by the compensation committee or the board of directors. Vested options
which are not exercised and unvested options, RSUs or PSUs return to the pool of reserved ordinary shares under the Plan for future grants.
The right to receive ordinary shares pursuant to PSUs granted under the Plan will vest upon the achievement of certain performance goals
to be established by the board of directors.

In the event of a merger, consolidation, reorganization or similar
transaction or our voluntary liquidation or dissolution, all of our unexercised vested equity grants and any unvested equity grants will
be automatically terminated. However, in the event of a change of control, or merger, consolidation, reorganization or similar transaction
resulting in the acquisition of at least 50% of our voting power, or the sale or transfer of all or substantially all of our outstanding
shares assets, the equity grants then outstanding may be assumed or substituted for an appropriate number of shares of each class of shares
or other securities and/or assets of the successor company in such transaction (or a parent or subsidiary or another affiliate of such
successor company) as were distributed to our shareholders in respect of the transaction. In addition to the foregoing, our board of directors
has approved the inclusion in the option agreements of the Company’s officers of a provision for accelerated vest